ArticleTropical medicine and health2026
Global and Chinese burden of three major non-communicable diseases attributable to high BMI: trends from 1990 to 2021 and projections to 2050.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic non‑communicable diseases (NCDs) are the leading cause of mortality worldwide. High body mass index (BMI) is a major modifiable risk factor for NCDs. This study aimed to compare temporal trends and age- and sex-specific patterns of high BMI-attributable NCD burden in China and globally from 1990 to 2021, disentangle the underlying drivers, and project the burden to 2050.
methodsWe used data from the Global Burden of Disease Study 2021 (GBD 2021) to estimate deaths and disability‑adjusted life years (DALYs) attributable to high BMI for neoplasms, cardiovascular diseases (CVDs), and diabetes mellitus in China and globally from 1990 to 2021. We applied Joinpoint regression, Age‑Period‑Cohort (APC) analysis, and decomposition analysis to identify temporal trends, inflection points, and driving factors, and used autoregressive integrated moving average (ARIMA) time series models to project future trends through 2050.
resultsIn 2021, age‑standardized mortality rates (ASMR) per 100,000 population in China attributable to high BMI were 2.81 (95% UI 1.20-4.76) for neoplasms, 18.80 (10.07-29.43) for CVDs, and 3.57 (1.37-5.72) for diabetes; corresponding age‑standardized DALY rates (ASDR) were 79.17 (33.82-134.14), 396.09 (197.27-638.54), and 292.46 (136.21-439.33), all higher than global averages. From 1990 to 2021, China showed positive AAPCs for neoplasms (ASMR, 2.4%; ASDR, 2.3%), CVDs (ASMR, 1.0%; ASDR, 1.1%), and diabetes (ASMR, 1.1%; ASDR, 2.3%). Compared with the corresponding global estimates, the increases were more pronounced for neoplasms, CVDs, and diabetes ASDR, whereas the diabetes ASMR trends were similar. Decomposition revealed that epidemiological change was the dominant driver in China, whereas population growth was the main driver globally, with smaller, outcome-specific contributions from aging. ARIMA projections suggested that the burden of high BMI-related NCDs in China may continue to increase through 2050, particularly for neoplasms and CVDs.
conclusionThe deaths and DALYs burden of NCDs attributable to high BMI in China and globally showed an increasing trend since 1990 and will continue increasing through 2050. Epidemiological changes were the predominant driver in China, whereas population growth was the main driver globally. Targeted screening and proactive weight-management strategies for high-risk populations may help mitigate the growing burden of high BMI-related NCDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.